Anales de la RANM

167 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 METASTATIC COLORECTAL CANCER Eduardo Díaz-Rubio An RANM · Año 2018 · número 135 (02) · páginas 160 a 168 14. Schwartzberg LS, Rivera F, Karthaus M et al.- PEAK: a randomized multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable wild-type KRAS exón 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-2247. 15. Rivera F, Karthaus M, Helcht JR et al.- Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-lie treament with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Di 2017; 32: 1179-1190. 16. Heineman V, Von Weikersthal LF, Decker T et al.- FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065- 1075. 17. Venouk AP, Niedzwiecki D, Lenz HJ, et al.- CALGB/ SWOG 80405: Phase III trial of irinotecan, 5-FU/ leucovorin (FOLFIRI) or oxaliplatin, 5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014; 32:5s (suppl; abstr LBA3). 18. Fearon ER, Volgestein B.- A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767. 19. Comprehensive molecular characterization of human colon and rectal cancer. The Cancer Genome Atlas Net work. Nature 2012; 487: 330-337. 20. Guinney J, Dienstmann R, Wang B et al.- The consensus molecular subtypes of colorectal cáncer. Nature Med 2015; 21: 1350-1356. 21. Garraway LA.- Genomic-driven oncology: Framework for an emerging paradigm. J Clin Oncol 2013; 31, 1806- 1814. 22. Sorich MJ, Wiese MD, Rowland A et al.- Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. AnnOncol 2015; 26: 13-21. 23. Sinicrope F; Okamoto K, Kasi P and Kawakami H.- Molecular biomarkers in the personalized treatment of colorectal cancer. Clin Gastroenterol Hepatol 2016; 14: 651-658. 24. Choi C, Al Bakir I, Hart A and Graham T.- Clonal evolution of colorectal cancer in IBD.- Nature Rev Gastroenterol Hepatol. 2017; 14: 218-229. 25. Punt CA; Koopman M and Vermeulen L.- From tumour heterogeneity to advances in precisión treatment of colorectal cancer. Nat Rev Clin Oncol 2017; 14: 235-246. 26. Atreya C, Yaeger R, and Chu E.- Systemic therapy of metastatic colorectal cancer: From current standars to future molecular targeted approaches. ASCO Educational Book 2017; 246-256. 27. Sartore-Bianchi A, Trusolino L, Martino C et al.- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codón 12/13 wild- type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicenter, open- label, phase 2 trial. Lancet Oncol 2016; 17: 738-746. 28. Cremolini C, Loupakis E, Antoniotti C et al.- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: Updated survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315. 29. Kopetz S, Mac Donough SL, Morris VK et al.- Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406). J Clin Oncol 2017;35, suppl 4S, abst 520. 30. Sanz-García E, Argiles G, Elez E, Tabernero J.- BRAF mutant colorectal cancer: prognosis, treatment and new perspectives. 2017;Ann Oncol 28: 2648-2657. 31. Van Cutsem E, Cuyle PJ, Huijberts S et al.- BEACON CRC study safety lead-in (SLI) in patients with BRAFV600E metastatic colorectal cancer: Efficacy and tumor markers. J Clin Oncol 2018; 36, suppl 4S, abs 627. 32. Dizon DS, Krilov L, Cohen E et al.- Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 2016; 34: 987-1011. 33. Burstein HJ, Krilov L, Aragon-Ching JB.- Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 2017;35: 1341-1367. 34. Heymach J; Krilov L; Alberg A et al.- Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer from the American Cancer Society of Clinical Oncology. J Clin Oncol 2018; 36: 1020-1044. 35. Le DT, Uram JN, Wang UH et al.- PD-1 Blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509-2520. 36. Overman M, Lonardi S, Wong KY et al.- Durable clinical benefit with Nivolumab Plus Ipilimumab in DNA mismatch repair-deficient microsatellite instability high metastatic colorectal cancer. J Clin Oncol 2018;36: 773-779. 37. Tauriello D, Palomo-Ponce S, Stork D et al.- TGFB drives immune evasión in genetically reconstituted colon cancer metástasis. 2018; Nature 554, 538-543. 38. Hamada T, Cao Y, Quian Z et al.- Aspirin use and colorectal cancer survival according to tumor CD274 (Programmed Cell Death 1 Ligand 1) expression status. J Clin Oncol 2017; 35: 1836-1844. 39. Díaz LA and Bardelli A.- Liquid Biopsies: Genotyping circulating tumor DNA. J Clin Oncol 2014; 32: 579- 586. 40. Siravegna G, Marsoni S, Siena S and Bardelli A.- Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol 2017;14: 531-548. 41. Bettegowda C; Sausen M; Leary et al.- Detection of circulating tumor DNA in early and late stage human malignancies. Sci Transl Med 2014; 6 (224): 224ra24. 42. Garcia-Foncillas J, Alba E, Aranda E, et al.- Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review. Ann Oncol 2017;28 (12): 2943-2949. 43. Tie J, Wang Y, Tomasetti C et al.- Circulating DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cáncer. Science Transl Med 2016; 346, 1-10. 44. Schmiegel W, Scott RJ, Dooley S et al.- Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol Oncol 2017; 11 (2): 209-219. 45. Normanno N, Esposito R, Lambiase M et al.- RAS testing of liquid biopsy correlates with the outcome of